Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ASP8731 in Healthy Adults
NCT05167526Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP8731 in sickle cell disease (SCD) (6 arms), sponsored by Astellas Pharma. Primary endpoints: Safety and tolerability assessed by nature, frequency, and severity of Adverse Events (AEs), Number of participants with laboratory value abnormalities and/or adverse events (AEs) and 2 more. Started Mar 2022; status: terminated.
02
Drugs
ASP8731
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05167526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167526.